Abstract
The effectiveness and efficiency of health care systems can be assessed by economic evaluation, comparing the costs and outcomes of alternative interventions. Direct costs include accommodation, nursing, physicians’ fees, diagnostic tests and treatment. Indirect costs derive from the loss of a persons ability to use life in a productive way e.g. employment. In cost-effectiveness analyses, cost is the numerator and effectiveness (related to health outcomes) is the denominator. The unit of measurement of effectiveness is usually years of life saved. Cost utility analyses require a preference-based measurement of health-related quality of life (HRQL) to allow the calculation of utility scores for health states and so the adjustment of effectiveness for quality. Typically, this allows the calculation of qualityadjusted life years (QALYs). A review of published reports, to be presented in detail, yields the following summation. The greater cost of stem cell harvest from peripheral blood is more than offset by the reduced costs associated with a shorter hospital stay. Transplants early in first remission cost less than those undertaken at later points in disease evolution/treatment experience. Changing the primary locus of care from inpatient to outpatient may result in notable cost savings but can produce cost-shifting (from inpatient to outpatient). Nevertheless, in selected patient, the use of non-myeloablative transplants may offer a cost-effective option, especially in the developing country context.
Similar content being viewed by others
References
Johnson PW, Simnett SJ, Sweetenham JW, Morgan GJ, Stewart LA. Bone marrow and peripheral blood stem cell transplantation for malignancy.Health Technol Assess. 1998;2: 1–187.
Weeks FM, Yee GC, Bartfield AA, Wingard JR. The true cost of bone marrow transplantation.Am J Med Sci. 1997; 314:101–112.
Hartmann O, Le Corroller AG, Blaise D, et al. Peripheral blood stem cell and bone marrow transplantation for solid tumours and lymphomas: Hematologic recovery and costs. A randomized, controlled trial.Ann Intern. 1997;126:600–607.
Barr RD, Furlong W, Horsman JR, Feeny D, Torrance GW, Weitzman S. The monetary costs of childhood cancer to the families of patients.Int J Oncol. 1996;8:933–940.
Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost Effectiveness in Health and Medicine. New York, Oxford University Press, 1996. pp1–425.
Durbin M. Bone marrow transplantation: Economic, ethical and social issues.Pediatrics. 1988;82:774–783.
Fletcher RH, Fletcher SW, Wagner EH. Clinical Epidemiology: The Essentials. Baltimore, Williams and Williams, 1996;5:2–6.
Jerjis SH, Croockweit S, Muus P, Schaap N, Preijers F, De-Witte T. Cost analysis of autologous peripheral stem cell transplantation versus autologous bone marrow transplantation for patient with non-Hodgkin’s lymphoma and acute lymphoblastic leukemia.Leuk Lymph. 1999;36:33–43.
Rizzo JD, Vogelsang GB, Krumm S, Frink B, Mock V, Bass EB. Outpatient-based bone marrow transplantation for hematologic malignancies: Cost saving or cost shifting?J Clin Oncol. 1999;17:2811–2818.
Barr R, Furlong W, Henwood J, et al. Economic evaluation of allogeneic bone marrow transplantation: A rudimentary model to generate estimates for the timely formulation of clinical policy.J Clin Oncol. 1996;14:1413–1420.
Dufoir T, Saux MC, Terraza B, et al. Comparative cost of allogeneic or autologous bone marrow transplantation and chemotherapy in patients with acute myeloid leukemia in first remission.Bone Marrow Transplant. 1992;10:323–329.
Uyl-de Groot CA, Hagenbeek A, Verdonck LF, Lowenberg B, Rutten FFH. Cost-effectiveness of ABMT in comparison with CHOP chemotherapy in patients with intermediate-and high-grade malignant non-Hodgkin’s lymphoma (NHL).Bone Marrow Transplant. 1995;16:463–470.
Beard MEJ, Inder AB, Allen JR, Hart DN, Heaton DC, Spearing RL. The costs and benefits of bone marrow transplantation.NZ Med J. 1991;104:303–305.
LeCoroller AG, Faucher C, Auperin A, et al. Autologous peripheral blood progenitor cell transplantation versus autologous bone marrow transplantation for adults and children with nonleukemic malignant disease. A randomized economic study.Pharmacoeconomics. 1997;11:454–463.
Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations.Can Med Assoc J. 1992;146:473–481.
Author information
Authors and Affiliations
About this article
Cite this article
Barr, R.D. The importance of lowering the costs of stem cell transplantation in developing countries. Int J Hematol 76 (Suppl 1), 365–367 (2002). https://doi.org/10.1007/BF03165286
Issue Date:
DOI: https://doi.org/10.1007/BF03165286